| February |
First Board of Directors Meeting is held at NordMedica SA in Lugano, Switzerland |
| February |
Ampicillin NordMedica 500 mg tablets is launched in Denmark |
| March |
Annual General Assembly is held in NordMedica A/S in Copenhagen, Denmark. Strong growth in sales and profit has been recorded for the financial year 2008 |
| March |
Pondocillin® 500 mg tablets is launched in NordMedica trade dress |
| July |
The market authorization for Nebcina is transferred to Eurocept International B.V., The Netherlands |
| August |
VibraNord® Oral Suspension is relaunched on the Swedish market |
| September |
Vibranord® Oral Suspension is launched on the Norwegian market |
| October |
NordMedica Business Development Managers to be present at CPhI Conference in Madrid, Spain |
| October |
The 3rd Meeting for Nordic Transplant Coordinators to be held in Copenhagen organized by NordMedica |
| December |
An agreement was signed with Wasserfall & Massing Medical Solutions GmbH, Berlin, Germany, for the promotion of two oncology products in 10 Eastern European EU countries and two Balkan countries |
| December |
Pondocillin® 700mg tablets is launched in NordMedica trade dress |
| January . |
A Nordic product portfolio of 8 products - Ampicillin, Dobutrex®, Doloxene®, Keflex®, Kefzol®, Neostigmin®, Pondocillin®, and Vancocin® was divested to Pharmacodane ApS, a subsidiary of German STADA Arzneimittel AG |
| May |
The NordMedica headquarter was succesfully relocated on May 3rd to Jægersborg Allé 164, 2820 Gentofte, Denmark. |
